
Sign up to save your podcasts
Or


Tim Boreham, Stockhead's small caps correspondent joins The Australian's Wealth Editor James Kirby on this week's show. They discuss how Biotech gets hit hardest of all, one reason this sector may recover first and three ASX biotech stocks for you to consider.
See omnystudio.com/listener for privacy information.
By The Australian4.5
1010 ratings
Tim Boreham, Stockhead's small caps correspondent joins The Australian's Wealth Editor James Kirby on this week's show. They discuss how Biotech gets hit hardest of all, one reason this sector may recover first and three ASX biotech stocks for you to consider.
See omnystudio.com/listener for privacy information.

12 Listeners

228 Listeners

85 Listeners

7 Listeners

13 Listeners

120 Listeners

7,080 Listeners

10 Listeners

56 Listeners

19 Listeners

1,820 Listeners

26 Listeners

342 Listeners

3 Listeners

289 Listeners

9 Listeners

29 Listeners

2 Listeners

21 Listeners

334 Listeners

115 Listeners

42 Listeners

239 Listeners

280 Listeners

6 Listeners

19 Listeners

18 Listeners

277 Listeners

6 Listeners

9 Listeners

12 Listeners

269 Listeners